第五届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、本次董事会由董事长刘继东先生召集，会议通知于 2025 年 9 月 25 日通 过电子邮件的形式送达至全体董事，董事会会议通知中包括会议的相关资料，同 时列明了会议的召开时间、地点、内容和方式。 2、本次董事会于 2025 年 9 月 28 日在公司会议室以现场与通讯会议相结合 的方式召开。 证券代码：300573 证券简称：兴齐眼药 公告编号：2025-045 沈阳兴齐眼药股份有限公司 3、本次董事会应到 9 人，实际出席会议人数为 9 人。 4、本次董事会由董事长刘继东先生主持，公司高级管理人员列席了本次董 事会。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法 律法规和《公司章程》的有关规定。 二、董事会会议审议情况 会议审议并通过了如下议案： （一）审议通过《关于调整公司 2021 年限制性股票激励计划授予价格及授 予数量的议案》 根据《沈阳兴齐眼药股份有限公司 2021 年限制性股票激励计划（草案）》等 相关规定和公司 2 ...

沈阳兴齐眼药股份有限公司（以下简称"公司"）于 2025 年 5 月 27 日召开 了第五届董事会第九次会议，审议通过了《关于公司 2025 年度向特定对象发行 股票预案的议案》。 2025 年 9 月 28 日，公司召开了第五届董事会第十一次会议，审议通过了《关 于公司 2025 年度向特定对象发行股票预案（修订稿）的议案》。《沈阳兴齐眼药 股份有限公司 2025 年度向特定对象发行股票预案（修订稿）》及相关文件于中国 证监会指定的创业板信息披露网站巨潮资讯网（http://www.cninfo.com.cn）上披 露，敬请投资者注意查询。 证券代码：300573 证券简称：兴齐眼药 公告编号：2025-050 沈阳兴齐眼药股份有限公司 关于 2025 年度向特定对象发行股票 预案（修订稿）披露的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 公司2025年度向特定对象发行股票预案的披露事项不代表审批机关对本次 发行股票相关事项的实质性判断、确认或批准。本预案所述本次向特定对象发行 股票相关事项的生效和完成尚需深圳证券交易所审核通过并经中国证监会 ...

证券代码：300573 证券简称：兴齐眼药 | 目 1 | 录 | | | --- | --- | --- | | 释 2 | 义 | | | 一、本次发行的背景和目的 4 | | | | （一）本次发行的背景 4 | | | | （二）本次发行的目的 5 | | | | 二、本次发行证券及其品种选择的必要性 6 | | | | （一）本次发行证券的品种 6 | | | | （二）本次发行证券品种选择的必要性 6 | | | | 三、本次发行对象的选择范围、数量和标准的适当性 7 | | | | （一）本次发行对象选择范围的适当性 7 | | | | （二）本次发行对象数量的适当性 7 | | | | （三）本次发行对象标准的适当性 8 | | | | 四、本次发行定价的原则、依据、方法和程序的合理性 8 | | | | （一）本次发行定价的原则和依据 8 | | | | （二）本次发行定价的方法和程序 9 | | | | 五、本次发行方式的可行性 9 | | | | （一）发行方式合法合规 9 | | | | （二）发行程序合法合规 12 | | | | 六、本次发行方案的公平性、合理性 12 | | | ...

授予价格及授予数量调整、第四个归属期归属条件成就 及部分限制性股票作废相关事项的 法律意见书 中国北京市朝阳区建国路77号华贸中心3号写字楼34层 邮政编码100025 电话: (86-10) 5809-1000 传真: (86-10) 5809-1100 北京市竞天公诚律师事务所 关于 沈阳兴齐眼药股份有限公司 2021年限制性股票激励计划 二〇二五年九月 | 一、 | 本次调整、归属及作废的批准与授权 5 | | --- | --- | | 二、 | 本次调整的相关事项 8 | | 三、 | 本次归属的相关事项 10 | | 四、 | 本次作废部分限制性股票情况 14 | | 五、 | 结论意见 14 | 对本法律意见书，本所及经办律师特作如下声明： 1、本所及经办律师依据《公司法》《证券法》《管理办法》《律师事务所从事 证券法律业务管理办法》《律师事务所证券法律业务执业规则（试行）》等法律法 规的规定以及本法律意见书出具日以前已经发生或者存在的事实为基础发表法 律意见。 2、本所及经办律师已根据有关法律法规的规定严格履行了法定职责，遵循 了勤勉尽责和诚实信用的原则，进行了充分的核查验证，保证本法律意见书 ...

Market Overview - The Shanghai Composite Index fell by 0.30% on September 19, with 16 industries rising, led by coal and non-ferrous metals, which increased by 1.97% and 1.19% respectively [2] - The automotive and pharmaceutical industries experienced the largest declines, with drops of 1.94% and 1.41% respectively [2] Capital Flow Analysis - The main capital outflow from the two markets totaled 58.733 billion yuan, with 8 industries seeing net inflows [2] - The non-ferrous metals industry had the highest net inflow, amounting to 872 million yuan, while the media industry followed with a net inflow of 692 million yuan and a daily increase of 0.49% [2] - A total of 23 industries experienced net capital outflows, with the computer industry leading at 10.723 billion yuan, followed by the automotive industry with 7.929 billion yuan [2] Pharmaceutical Industry Performance - The pharmaceutical industry saw a decline of 1.41% with a total net capital outflow of 7.085 billion yuan [3] - Out of 474 stocks in the pharmaceutical sector, 65 stocks rose while 405 stocks fell, including one stock hitting the daily limit down [3] - The top three stocks with the highest net inflow in the pharmaceutical sector were: - Borui Pharmaceutical with a net inflow of 130 million yuan - Mindray Medical with 75.259 million yuan - Micron Technology with 73.759 million yuan [3][4] Capital Outflow in Pharmaceutical Sector - The stocks with the largest capital outflows included: - China National Pharmaceutical with a net outflow of 406 million yuan - Furuya Shares with 342 million yuan - Xingqi Eye Medicine with 188 million yuan [5] - Other notable outflows included: - Hengrui Medicine with a net outflow of 172 million yuan - Celgene Medical with 158 million yuan [5][6]

Core Viewpoint - On September 19, Xingqi Eye Pharmaceutical experienced a decline of 5.1%, with a stock price of 67.96 yuan per share, a trading volume of 872 million yuan, a turnover rate of 6.64%, and a total market capitalization of 16.674 billion yuan [1] Company Overview - Xingqi Eye Pharmaceutical Co., Ltd. is located in Shenyang, Liaoning Province, and was established on March 24, 1977, with its listing date on December 8, 2016 [1] - The company's main business involves the research, production, and sales of ophthalmic drugs, with revenue composition as follows: eye drops 82.15%, gel/eye ointment 16.70%, and others 1.15% [1] Shareholder Information - Southern Fund's Southern CSI 500 ETF (510500) is among the top ten circulating shareholders of Xingqi Eye Pharmaceutical, having increased its holdings by 764,100 shares in the second quarter, totaling 2.5163 million shares, which represents 1.34% of the circulating shares [2] - The estimated floating loss for the ETF today is approximately 9.1846 million yuan [2] - The Southern CSI 500 ETF was established on February 6, 2013, with a latest scale of 113.438 billion yuan, and has achieved a year-to-date return of 27.4% [2] Fund Performance - The Southern Big Data 300 Index A (001420) holds 47,800 shares of Xingqi Eye Pharmaceutical, accounting for 0.93% of the fund's net value, ranking as the seventh largest holding [3] - The estimated floating loss for this fund today is about 174,300 yuan [3] - The Southern Big Data 300 Index A was established on June 24, 2015, with a latest scale of 2.17 billion yuan, and has achieved a year-to-date return of 37% [3]

Core Viewpoint - The company emphasizes its competitive advantage with the only approved eye medication for delaying myopia progression in children, while maintaining stable pricing despite market competition and potential new entrants [1] Group 1 - The company has the first and only officially approved eye medication in China for delaying myopia progression in children, known as Xingqi® Meiyoupin® [1] - Two additional concentrations of atropine eye drops (0.02% and 0.04%) have completed phase III clinical trial summary reports, which will enhance the company's myopia prevention product matrix upon their market launch [1] - Currently, the approved product is not included in centralized procurement, allowing the company to maintain stable pricing in the competitive market [1]

Group 1 - The chemical pharmaceutical sector experienced a decline of 0.2% on September 17, with Warner Pharmaceuticals leading the drop [1] - The Shanghai Composite Index closed at 3876.34, up 0.37%, while the Shenzhen Component Index closed at 13215.46, up 1.16% [1] - Notable gainers in the chemical pharmaceutical sector included ST Tian Sheng, which rose by 4.97% to a closing price of 5.28, and Bai Li Tian Heng, which increased by 4.08% to 372.00 [1] Group 2 - Warner Pharmaceuticals saw a significant decline of 9.22%, closing at 57.92, contributing to the overall downturn in the sector [2] - Other notable decliners included Anglikang, down 4.53% to 41.28, and Guangsheng Tang, down 4.40% to 111.91 [2] - The sector experienced a net outflow of 1.541 billion yuan from major funds, while retail investors saw a net inflow of 1.516 billion yuan [2][3] Group 3 - Major fund inflows were observed in companies like Heng Rui Pharmaceutical, which had a net inflow of 3.43 million yuan, while retail investors showed a net outflow of 58.13 million yuan [3] - The top net inflows from retail investors were seen in Hai Zheng Pharmaceutical, with 34.03 million yuan, and Hua Yuan Biological, with 30.05 million yuan [3] - The overall trend indicates a shift in investment dynamics within the chemical pharmaceutical sector, with retail investors showing resilience despite major fund outflows [3]

Core Viewpoint - The report from Dongfang Securities indicates that Xingqi Eye Medicine achieved a net profit attributable to shareholders of 335 million yuan in the first half of 2025, representing a year-on-year increase of 97.8% [1] - The strong performance is attributed to robust growth in core products such as atropine and cyclosporine eye drops, along with improved profit margins due to an optimized product mix [1] Financial Performance - The net profit excluding non-recurring items reached 331 million yuan, reflecting a year-on-year increase of 96.3% [1] - The gross profit margin improved by 2.5 percentage points year-on-year, driven by a higher proportion of high-margin product revenue [1] - The company effectively controlled expenses, with the combined expense ratio (sales, management, and R&D) decreasing by 8.7 percentage points year-on-year [1] Future Outlook - With the accelerated market penetration of low-concentration atropine, the company is expected to see accelerated growth in performance and sustained improvement in profitability [1] - Using a discounted cash flow valuation method, the estimated fair market value of the company is projected to be 19.675 billion yuan, corresponding to a target price of 80.19 yuan per share, maintaining a "buy" rating [1]

Group 1 - The core point of the article is that Xingqi Eye Medicine announced its cash dividend distribution plan for the first half of 2025, which is 7.00 yuan per 10 shares (including tax) [1] - The record date for the dividend distribution is set for September 23, 2025 [1] - The ex-dividend date is scheduled for September 24, 2025 [1]